Literature DB >> 26000106

Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA - evidence-based immunology?

Elena Csernok1, Julia U Holle1.   

Abstract

Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, and primary pauci-immune crescentic glomerulonephritis are associated with circulating antineutrophil cytoplasmic autoantibodies (ANCA) (collectively called ANCA-associated vasculitides, AAV). Two types of ANCA, one with a cytoplasmic fluorescence pattern (C-ANCA) and specificity for proteinase 3 (PR3-ANCA) and the other with a perinuclear pattern (P-ANCA) and specificity for myeloperoxidase (MPO-ANCA), account for this association and are highly specific markers for these vasculitides. AAV most often require therapy with cytotoxic and antiinflammatory agents, and hence a well-established diagnosis is mandatory to avoid unnecessary and risky treatment. The widespread use of ANCA screening in the past decade has resulted in the occurrence of greater numbers of false-positive results and has led to greater difficulty in test interpretation. Methods for ANCA detection have been standardized internationally in large multicentre studies and an international consensus statement on testing and reporting of ANCA has been pub lished (1999 and 2003). Despite these advances, problems with the extended use of ANCA testing in daily clinical practice remain. They may be summarized as follows: (1) the basic standards for ANCA testing are not uniformly met; (2) there is still controversy over the value of formalin fixation of neutrophils in differentiating P-ANCA from antinuclear antibodies (what is the place of this substrate in ANCA testing?); (3) the new generation of PR3-ANCA and MPO-ANCA ELISAs are more sensitive and specific than immunofluorescence testing (should ELISAs replace the immunofluorescence test?); and (4) should alternative methods for ANCA detection such as image analysis and/or multiplex immunoassays be used for screening? In this paper, we review these issues, identify areas of uncertainty, and provide practical guidelines where possible.

Entities:  

Keywords:  ANCA; ANCA-associated vasculitides; Myeloperoxidase; Proteinase 3; Screening

Year:  2010        PMID: 26000106      PMCID: PMC4389065          DOI: 10.1007/s13317-010-0007-3

Source DB:  PubMed          Journal:  Auto Immun Highlights        ISSN: 2038-0305


  12 in total

1.  Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?

Authors:  J U Holle; B Hellmich; M Backes; W L Gross; E Csernok
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

Review 2.  Diagnostic significance of ANCA in vasculitis.

Authors:  Elena Csernok; Peter Lamprecht; Wolfgang L Gross
Journal:  Nat Clin Pract Rheumatol       Date:  2006-04

3.  The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis.

Authors:  J K Rao; M Weinberger; E Z Oddone; N B Allen; P Landsman; J R Feussner
Journal:  Ann Intern Med       Date:  1995-12-15       Impact factor: 25.391

4.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.

Authors:  E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

5.  Image analysis: a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener's granulomatosis.

Authors:  Maarten M Boomsma; Jan G M C Damoiseaux; Coen A Stegeman; Cees G M Kallenberg; Meeta Patnaik; James B Peter; Jan W Cohen Tervaert
Journal:  J Immunol Methods       Date:  2003-03-01       Impact factor: 2.303

6.  Testing on formalin-fixed neutrophils is less sensitive and specific for small vessel vasculitis, and less sensitive for MPO-ANCA, than most ELISAs.

Authors:  Wendy Pollock; Michelle Trevisin; Judy Savige
Journal:  J Immunol Methods       Date:  2008-09-26       Impact factor: 2.303

7.  Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease (IBD).

Authors:  Michelle Trevisin; Wendy Pollock; Wayne Dimech; Judy Savige
Journal:  J Immunol Methods       Date:  2008-04-25       Impact factor: 2.303

8.  Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis.

Authors:  Renate Kain; Markus Exner; Ricarda Brandes; Reinhard Ziebermayr; Dawn Cunningham; Carol A Alderson; Agnes Davidovits; Ingrid Raab; Renate Jahn; Oliver Ashour; Susanne Spitzauer; Gere Sunder-Plassmann; Minoru Fukuda; Per Klemm; Andrew J Rees; Dontscho Kerjaschki
Journal:  Nat Med       Date:  2008-10-05       Impact factor: 53.440

9.  A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3.

Authors:  B Hellmich; E Csernok; G Fredenhagen; W L Gross
Journal:  Clin Exp Rheumatol       Date:  2007 Jan-Feb       Impact factor: 4.473

10.  Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study.

Authors:  Elena Csernok; Julia Holle; Bernhard Hellmich; Jan Willem; Cohen Tervaert; Cees G M Kallenberg; Peter C Limburg; John Niles; Gouli Pan; Ulrich Specks; Kerstin Westman; Jörgen Wieslander; Kirsten De Groot; Wolfgang L Gross
Journal:  Rheumatology (Oxford)       Date:  2003-10-29       Impact factor: 7.580

View more
  9 in total

1.  A challenging diagnosis of MPO-C-ANCA EGPA.

Authors:  Gareth Lim; Sheryl Lim; Shang-Ian Tee; Chai Yiing Ling
Journal:  BMJ Case Rep       Date:  2019-07-10

Review 2.  Current and emerging techniques for ANCA detection in vasculitis.

Authors:  Elena Csernok; Frank Moosig
Journal:  Nat Rev Rheumatol       Date:  2014-06-03       Impact factor: 20.543

Review 3.  ANCA testing: the current stage and perspectives.

Authors:  Elena Csernok
Journal:  Clin Exp Nephrol       Date:  2012-11-23       Impact factor: 2.801

4.  Automation, consolidation, and integration in autoimmune diagnostics.

Authors:  Renato Tozzoli; Federica D'Aurizio; Danilo Villalta; Nicola Bizzaro
Journal:  Auto Immun Highlights       Date:  2015-07-03

5.  Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis.

Authors:  Daniel Smyk; Eirini I Rigopoulou; Nicola Bizzaro; Dimitrios P Bogdanos
Journal:  Auto Immun Highlights       Date:  2012-01-13

6.  MPO-C-ANCA-associated necrotising and crescentic glomerulonephritis.

Authors:  Abhilash Koratala; Dara N Wakefield; Kawther F Alquadan; A Ahsan Ejaz
Journal:  JRSM Open       Date:  2017-04-03

7.  Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis.

Authors:  Ilka Knütter; Rico Hiemann; Therese Brumma; Thomas Büttner; Kai Großmann; Marco Cusini; Francesca Pregnolato; Maria Orietta Borghi; Ursula Anderer; Karsten Conrad; Dirk Reinhold; Dirk Roggenbuck; Elena Csernok
Journal:  Arthritis Res Ther       Date:  2012-12-14       Impact factor: 5.156

8.  Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.

Authors:  Mandy Sowa; Kai Grossmann; Ilka Knütter; Rico Hiemann; Nadja Röber; Ursula Anderer; Elena Csernok; Dimitrios P Bogdanos; Maria Orietta Borghi; Pier Luigi Meroni; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

Review 9.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.